表紙
市場調査レポート

INSYS Therapeutics, Inc.:製品パイプライン分析

INSYS Therapeutics, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224713
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
INSYS Therapeutics, Inc.:製品パイプライン分析 INSYS Therapeutics, Inc. - Product Pipeline Review - 2016
出版日: 2016年04月20日 ページ情報: 英文 45 Pages
概要

INSYS Therapeutics, Inc.では、化学療法誘発性悪心嘔吐(CINV)に対処するための革新的製品の創薬・開発・販売に取り組んでいます。特に、化学療法の副作用向けの治療薬や、疼痛管理・中枢神経系(CNS)向け治療法の開発を集中的に進めています。同時に、吸引式および室温カプセル/シロップ式のドロナビノールの開発も展開してます。同社では更に、革新的なドラッグデリバリ・システムを用いた、既存の医薬品の有効活用方法をも開発しようとしています。

当レポートでは、米国のバイオ医薬品企業、INSYS Therapeutics, Inc.(INSYS Therapeutics)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

INSYS Therapeutics, Inc.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • 単剤治療薬
  • 併用療法モダリティ

パイプライン製品の概要

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第?相にある製品/併用療法モダリティ
  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ

薬剤のプロファイル

  • ドロナビノール
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • 塩酸ブプレノルフィン
  • カンナビジオール
  • (塩酸ブプレノルフィン + 塩酸ナロキソン)
  • 塩酸ナロキソン
  • 塩酸オンダンセトロン
  • パクリタキセル
  • セチリジン塩酸塩 + クロモグリク酸ナトリウム
  • ジクロフェナクナトリウム
  • ケトロラクトロメタミン
  • クエン酸シルデナフィル

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

開発が中止された製品

  • 開発が中止された製品のプロファイル
    • 腫瘍学向けメソテリンを標的としたモノクローナル抗体複合体

企業のステートメント

事業所および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08027CDB

Summary

Global Markets Direct's, 'INSYS Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the INSYS Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of INSYS Therapeutics, Inc.
  • The report provides overview of INSYS Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses INSYS Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features INSYS Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate INSYS Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for INSYS Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding INSYS Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • INSYS Therapeutics, Inc. Snapshot
    • INSYS Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • INSYS Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • INSYS Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • INSYS Therapeutics, Inc. - Pipeline Products Glance
    • INSYS Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • INSYS Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • INSYS Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • INSYS Therapeutics, Inc. - Drug Profiles
    • dronabinol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cannabidiol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetirizine hydrochloride + cromolyn sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diclofenac sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketorolac tromethamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • INSYS Therapeutics, Inc. - Pipeline Analysis
    • INSYS Therapeutics, Inc. - Pipeline Products by Target
    • INSYS Therapeutics, Inc. - Pipeline Products by Route of Administration
    • INSYS Therapeutics, Inc. - Pipeline Products by Molecule Type
    • INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • INSYS Therapeutics, Inc. - Recent Pipeline Updates
  • INSYS Therapeutics, Inc. - Dormant Projects
  • INSYS Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology
  • INSYS Therapeutics, Inc. - Company Statement
  • INSYS Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • INSYS Therapeutics, Inc., Key Information
  • INSYS Therapeutics, Inc., Key Facts
  • INSYS Therapeutics, Inc. - Pipeline by Indication, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Pre-Registration, 2016
  • INSYS Therapeutics, Inc. - Phase III, 2016
  • INSYS Therapeutics, Inc. - Phase II, 2016
  • INSYS Therapeutics, Inc. - Phase I, 2016
  • INSYS Therapeutics, Inc. - Preclinical, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Target, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • INSYS Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • INSYS Therapeutics, Inc. - Dormant Developmental Projects,2016
  • INSYS Therapeutics, Inc. - Discontinued Pipeline Products, 2016
  • INSYS Therapeutics, Inc., Other Locations
  • INSYS Therapeutics, Inc., Subsidiaries

List of Figures

  • INSYS Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • INSYS Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top